Bayer will vigorously defend itself against Kogenate patent infringement suit filed by Novartis
Bayer confirms that the company has received a joint complaint filed by Novartis Vaccines and Diagnostics Inc. and Novo Nordisc A/S in the US. The plaintiffs allege that, through production and distribution of the recombinant factor VIII product KogenateŽ, the company infringes a compound patent issued in 2006. Essentially, the plaintiffs claim patent infringement and compensation.
Bayer will vigorously defend itself against the complaint. Bayer is of the opinion not to infringe on any valid patent claim of Novartis.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.